<DOC>
	<DOC>NCT00731692</DOC>
	<brief_summary>The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.</brief_summary>
	<brief_title>FTY720 in Patients With Primary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>General 1. sign written informed consent prior to participating in the study 2. 25 through 65 years of age inclusive 3. females of childbearing potential must: have a negative pregnancy test at Baseline (prior to randomization) and use simultaneously two forms of effective contraception during the treatment and 3months after discontinuation of study medication Primary Progressive Multiple sclerosis. 1. diagnosis of primary progressive multiple sclerosis (according to the 2005 Revised McDonald criteria): 2. time since first reported symptoms between 2 and 10 years 3. evidence of clinical disability progression in the 2 years prior to Screening 4. disability status at Screening EDSS score of 3.56.0 inclusive pyramidal functional system score of 2 or more 25'TWT less than 30 seconds PPMS specific: History of relapses/attacks Progressive neurological disorder other than PPMS Pure cerebellar syndrome or pure visual progressive syndrome or pure cognitive progressive syndrome Presence of spinal cord compression at screening MRI Relevant history of vitamin B12 deficit Evidence of syphilis or borreliosis at Screening Cardiovascular conditions: Myocardial infarction within the past 6 months or current unstable ischemic heart disease History of angina pectoris due to coronary spasm or history of Raynaud's phenomenon Severe cardiac failure or cardiac arrest History of symptomatic bradycardia Resting pulse &lt;55 bpm predose History of sick sinus syndrome or sinoatrial heart block History or presence of second and third degree AV block or an increase QT interval (QTc&gt;440 ms) Arrythmia requiring treatment with class III antiarrythmic drugs History of positive tilt test from workout of vasovagal syncope Hypertension, not controlled with medication Pulmonary: Severe respiratory disease or pulmonary fibrosis TB Abnormal Xray, suggestive of active pulmonary disease Abnormal PFT: &lt;70% of predicted for FEV1 and FVC; &lt;60% for DLCO Patients receiving chronic (daily) therapies for asthma Hepatic: Known history of alcohol abuse, chronic liver or biliary disease Total or conjugated Brb &gt;ULN, unless in context of Gilbert's syndrome AP &gt;1.5xULN; ALT/AST &gt;2xULN; GGT&gt;3xULN Other: History of chronic disease of the immune system other than MS Malignancy (other than successfully treated SCC or BCC) Diabetes Mellitus Macular Edema present at screening HIV, Hepatitis C or B, other active infection History of total lymphoid irradiation or bone marrow transplantation Serum creatinine &gt;1.7 mg/dl WBC &lt;3500 cells/mm3 Lymphocyte count &lt;800 cells/mm3 History of substance abuse or any other factor that may interfere with subject ability to cooperate and comply with the study procedures Unable to undergo MRI scans Participation in any therapeutical clinical research study in the 6 months prior to randomization Pregnant or lactating women Drugs requiring washout period: 3 months: Systemic corticosteroids or ACTH INFbeta 6 months: Immunosuppressive medication Immunoglobulins Monoclonal antibodies Drugs that exclude participation in the study: Cladribine Cyclophosphamide Mitoxantrone (except: patients who received a cumulative dose of no more than 60mg/m2 more than 5 years ago could enter the study) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>FTY720, primary progressive multiple sclerosis,PPMS</keyword>
</DOC>